The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
The PD-1–PD-L pathway in immunological tolerance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Self-citationSteinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Self-citation
Cited by
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Self-citationImmune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Satpathy, A. T., Granja, J. M., Yost, K. E., Qi, Y., Meschi, F., McDermott, G. P., Olsen, B. N., Mumbach, M. R., Pierce, S. E., Corces, M. R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0206-z · Cited by 980
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection
Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02844-06 · Cited by 920
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
“In contrast to cytotoxic T-lymphocyte antigen-4 (CTLA-4) deficiency, which leads to a massive lymphoproliferative disorder within weeks of birth (7), PD-1 deficiency leads to species-specific autoimmunity that occurs much later in life (2).”
BackgroundSharma, M. D., Baban, B., Chandler, P., Hou, D.-Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 792
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Haynes, N. M., Allen, C. D. C., Lesley, R., Ansel, K. M., Killeen, N., & Cyster, J. G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5099 · Cited by 694
Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & Tokura, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 667
Self-citationClinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
Urbani, S., Amadei, B., Tola, D., Massari, M., Schivazappa, S., Missale, G., & Ferrari, C. (2006) · Journal of Virology · doi:10.1128/jvi.01177-06 · Cited by 588
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
Huang, X., Venet, F., Wang, Y. L., Lepape, A., Yuan, Z., Chen, Y., Swan, R., Kherouf, H., Monneret, G., Chung, C.-S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809422106 · Cited by 515
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Blank, C., & Mackensen, A. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0272-1 · Cited by 505
The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
Kawamoto, S., Tran, T. H., Maruya, M., Suzuki, K., Doi, Y., Tsutsui, Y., Kato, L. M., & Fagarasan, S. (2012) · Science · doi:10.1126/science.1217718 · Cited by 451
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
Self-citationImmunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
PD-1 and its ligands in T-cell immunity
Keir, M. E., Francisco, L. M., & Sharpe, A. H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.012 · Cited by 431
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C., Huber, X., Zlobec, I., Eppenberger-Castori, S., Tzankov, A., Rosso, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.015 · Cited by 431
NFATc1 Regulates PD-1 Expression upon T Cell Activation
Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416
Regulation of microglial activation in stroke
Zhao, S.-C., Ma, L.-S., Chu, Z.-H., Xu, H., Wu, W.-Q., & Liu, F. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.162 · Cited by 410
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
Freeman, G. J., Wherry, E. J., Ahmed, R., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061800 · Cited by 399
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
Wang, T., Wang, D., Yu, H., Feng, B., Zhou, F., Zhang, H., Zhou, L., Jiao, S., & Li, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-03915-4 · Cited by 391
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
Ye, B., Liu, X., Li, X., Kong, H., Tian, L., & Chen, Y. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.42 · Cited by 391
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21335 · Cited by 378
Regulation and Functions of Blimp-1 in T and B Lymphocytes
Martins, G., & Calame, K. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090241 · Cited by 372
Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J. A., Castelblanco, N., & Rosen, H. R. (2007) · Journal of Virology · doi:10.1128/jvi.00409-07 · Cited by 371
Negative signaling by inhibitory receptors: the NK cell paradigm
Long, E. O. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00660.x · Cited by 370
The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Marzagalli, M., Ebelt, N. D., & Manuel, E. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.002 · Cited by 345
Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis
Lázár-Molnár, E., Chen, B., Sweeney, K. A., Wang, E. J., Liu, W., Lin, J., Porcelli, S. A., Almo, S. C., Nathenson, S. G., & Jacobs, W. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007394107 · Cited by 338
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
Creating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2233 · Cited by 327
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I.-M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 324
Self-citationPD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence
Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 306
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
The yin and yang of evasion and immune activation in HCC
Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 293
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review
Marini, A., Bernardini, A., Gigli, G. L., Valente, M., Muñiz-Castrillo, S., Honnorat, J., & Vogrig, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011795 · Cited by 273
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Wang, J., Okazaki, I.-M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 270
Self-citationLi, Y., Liang, L., Dai, W., Cai, G., Xu, Y., Li, X., Li, Q., & Cai, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0539-x · Cited by 270
Dendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage
Perrot, I., Blanchard, D., Freymond, N., Isaac, S., Guibert, B., Pachéco, Y., & Lebecque, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2763 · Cited by 266
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Kido, M., Watanabe, N., Okazaki, T., Akamatsu, T., Tanaka, J., Saga, K., Nishio, A., Honjo, T., & Chiba, T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.042 · Cited by 119
Self-citationPD-1 regulates extrathymic regulatory T-cell differentiation
Chen, X., Fosco, D., Kline, D. E., Meng, L., Nishi, S., Savage, P. A., & Kline, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344423 · Cited by 107
Okamura, T., Yamamoto, K., & Fujio, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00340 · Cited by 41
Nan, X.-P., Zhang, Y., Yu, H.-T., Li, Y., Sun, R.-L., Wang, J.-P., & Bai, X.-F. (2010) · Viral Immunology · doi:10.1089/vim.2009.0061 · Cited by 37
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2006-04
- Volume
- 27
- Issue
- 4
- Pages
- 195-201
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2013013791
- Cited by
- 721
- References
- 66
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.